Weight Loss Now Drives Global GLP-1 Usage Over Diabetes Management

According to a new survey from Numerator, 11.1% of US households have at least one member taking GLP-1s purely for weight loss, compared to 9.7% using them for diabetes management or a combination of both conditions. It's a quiet inflection — and for anyone watching the relationship between what we eat and why we eat it, the ripple effects reach well beyond the pharmacy counter.

A global pattern is taking root

This isn't just an American story. Kantar's global study, spanning markets from the UK to India and China, found that 79% of GLP-1 users worldwide are taking the drugs for weight loss alone. In every market surveyed except one, weight loss has become the dominant reason for use — a complete inversion of the landscape as recently as late 2024, when diabetes management still led by a wide margin.

The prescription pathway itself is shifting. Where primary care physicians once wrote most GLP-1 scripts, Kantar reports a noticeable migration toward specialists, weight loss clinics, and digital-first platforms, with retail and online pharmacies stepping into a larger fulfillment role. And with the Ozempic patent lapsing this year across many markets — including China, India, and Canada — the coming wave of generic semaglutide options is likely to accelerate adoption further.

Your grocery cart is quietly rewriting itself

Here's where it gets genuinely interesting for those of us who think in terms of food systems rather than just prescriptions. Numerator's data shows that households with GLP-1 users have cut grocery spending by 3.8%. But the story isn't simply about buying less — it's about buying differently. These households are migrating away from the pantry's carb-centric backbone: pasta, bakery items, shelf-stable staples. In their place, fresh protein, seafood, functional nutrition products, and what Numerator calls "more intentional snacking" are gaining ground.

I find this data point quietly fascinating. It mirrors patterns I've seen in fieldwork around ancestral and whole-food diets — when people's appetites shift, their relationship with the center aisles of the supermarket shifts with them. The pantry, once the gravitational core of American grocery shopping, is losing its pull.

Adoption is surging — but staying power is the real question

More than 22% of US households now include at least one GLP-1 user — double the rate from just October 2023. These households represent an extraordinary $660 billion in combined spending across consumer packaged goods, general merchandise, and quick-service restaurants, making them a demographic that food brands and retailers can no longer afford to overlook.

Yet the retention story complicates the picture. Nearly two-thirds of former users discontinue treatment within six months, meaning today's market is shaped heavily by recent adopters rather than long-term adherents. Only about a quarter of active users say they plan to stop at some point, and roughly 40% of former users report they would return if their health worsened. Kantar puts it plainly: for many, GLP-1 use is "likely not a one-time engagement."

What this means for you: If you're among the millions now navigating nutrition on GLP-1 therapy — or considering it — the practical takeaway is woven right into the data. These drugs don't just suppress appetite; they seem to reshape the very architecture of how people shop and eat. That makes intentional food planning not a nice-to-have but a necessity. Focus on protein density, micronutrient-rich whole foods, and fiber — the building blocks your body still needs even when hunger signals soften. And if you do discontinue, have a nutrition strategy ready. The shift in appetite can be abrupt, and the return to old patterns is precisely where many people struggle most.